Browse > Article

Sequential use of Intramuscular and Oral Progesterone for Luteal Phase Support in in vitro Fertilization  

Kim, Sang-Don (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital)
Jee, Byung-Chul (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital)
Lee, Jung-Ryeol (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital)
Suh, Chang-Suk (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital)
Kim, Seok-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Moon, Shin-Yong (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Publication Information
Clinical and Experimental Reproductive Medicine / v.37, no.1, 2010 , pp. 41-48 More about this Journal
Abstract
Objectives: The aim of this study was to assess appropriate time to convert intramuscular progesterone support to oral administration for luteal phase support in in vitro fertilization (IVF). Methods: Seventy-six cycles of IVF in which fetal heart beat was identified after treatment were included. Patients underwent controlled ovarian hyperstimulation with GnRH agonist long protocol (n=7) or GnRH antagonist protocol (n=66). Cryopreserved embryo transfer was performed in three cycles. Luteal support was initiated by daily intramuscular injection of progesterone, and after confirmation of fetal heart beat, converted to oral micronized progesterone (Utrogestan, Laboratoires Besins International, France) 300 mg daily before or after 8 gestational weeks. The oral progesterone was continued for 11 weeks. Results: Overall clinical abortion rate was 3.9% (3/76) and mean time to conversion was $8^{+4}$ gestational weeks ($46{\pm}5.8$ days after oocytes retrieval). The abortion rate was 5.6% (1/17) and 3.4% (2/59) in patients with conversion before 7 weeks and after 8 weeks, respectively, which were not statistically significant (p=0.678). The miscarriages were occurred at $9^{+4}$ weeks, $11^{+3}$ weeks and $11^{+4}$ weeks. Conclusion: Sequential luteal support using intramuscular and oral progesterone yields a relatively low clinical abortion rate. If fetal heart beat confirmed, sequential regimen appears to be safe and convenient method to reduce patients' discomfort induced by multiple injections.
Keywords
Luteal phase support; Oral progesterone; In vitro fertilization;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hubayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertil Steril 2008; 89: 749-58.   DOI   ScienceOn
2 Costabile L, Gerli S, Manna C, Rossetti D, Di Renzo GC, Unfer V. A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril 2001; 76: 394-6.   DOI   ScienceOn
3 Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Ann Emerg Med 2006; 47: 472-5.   DOI   ScienceOn
4 Doody KJ, Schnell VL, Foulk RA, Miller CE, Kolb BA, Blake EJ, et al. Endometrin for luteal phase support in a randomized, controlled, open label, prospective IVF clinical trial using a combination of menopur and bravelle. Fertil Steril 2009; 91: 1012-7.   DOI   ScienceOn
5 Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol 2002; 103: 48-52.   DOI   ScienceOn
6 Penzias AS. Luteal phase support. Fertil Steril 2002; 77: 318-23.   DOI   ScienceOn
7 Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17: 357-61.   DOI   ScienceOn
8 Zinaman MJ, Clegg ED, Brown CC, O'Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65: 503-9.   DOI
9 Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod 1996; 11: 406-12.   DOI
10 Tong S, Kaur A, Walker SP, Bryant V, Onwude JL, Permezel M. Miscarriage risk for asymptomatic women after a normal first-trimester prenatal visit. Obstet Gynecol 2008; 111: 710-4.
11 Ng EH, Miao B, Cheung W, Ho PC. A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. Eur J Obstet Gynecol Reprod Biol 2003; 111: 50-4.   DOI   ScienceOn
12 Scott R, Navot D, Liu HC, Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril 1991; 56: 481-4.   DOI
13 Jarvelä IY, Ruokonen A, Tekay A. Effect of rising hCG levels on the human corpus luteum during early pregnancy. Hum Reprod 2008; 23: 2775-81.   DOI   ScienceOn
14 Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 2007; 23 Suppl 1: 68-72.   DOI   ScienceOn
15 Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles. Hum Reprod 2006; 21: 905-8.   DOI
16 Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 2005; 97: 416-20.   DOI   ScienceOn
17 Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999; 14: 1944-8.   DOI
18 Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet AL, Dehaene JL. Luteal support after luteinizing hormonereleasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone. Fertil Steril 1990; 53: 490-4.   DOI
19 Smitz J, Bourgain C, Van Waesberghe L, Camus M, Devroey P, Van Steirteghem AC. A prospective randomized study on estradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG-induced superovulation. Hum Reprod 1993; 8: 40-5.   DOI
20 Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant folliclestimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186-92.   DOI   ScienceOn
21 Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular administration of progesterone as luteal phase support after IVF: case report. Hum Reprod 2004; 19: 1806 -10   DOI   ScienceOn
22 Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996; 11: 2085-9.   DOI   ScienceOn
23 Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, et al. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Fertil Steril 2008; 89: 860-7.   DOI   ScienceOn
24 Lightman A, Kol S, Itskovitz-Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Hum Reprod 1999; 14: 2596-9.   DOI
25 Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992; 7: 1225-9.   DOI
26 Szekeres-Bartho J, Balasch J. Progestagen therapy for recurrent miscarriage. Hum Reprod Update 2008; 14: 27-35.
27 Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril 2008; 89: 458-67.   DOI   ScienceOn
28 Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril 2009; 92: 163-9.   DOI   ScienceOn
29 Iwase A, Ando H, Toda S, Ishimatsu S, Harata T, Kurotsuchi S, et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Arch Gynecol Obstet 2008; 277: 319-24.   DOI   ScienceOn
30 Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999; 71: 614-8.   DOI   ScienceOn
31 Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a metaanalysis of the randomized trials. Hum Reprod 2002; 17: 2287-99.   DOI   ScienceOn
32 Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004: CD004830.
33 Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing crinone 8% and intramuscular progesterone supplementation in in vitro fertilizationembryo transfer cycles. Fertil Steril 2001; 76: 1144-9.   DOI   ScienceOn
34 Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115: 759-65.   DOI
35 Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (crinone 8%) or intramuscular (prontogest) progesterone: results of a prospective randomized study. Minerva Ginecol 2001; 53: 297-301.
36 Abate A, Perino M, Abate FG, Brigandì A, Costabile L, Manti F. Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clin Exp Obstet Gynecol 1999; 26: 203-6.
37 Csapo AI, Pulkkinen MO, Kaihola HL. The relationship between the timing of luteectomy and the incidence of complete abortions. Am J Obstet Gynecol 1974; 118: 985-9.   DOI
38 Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 2007; 13: 581-90.   DOI   ScienceOn
39 Bergeron C. Morphological changes and protein secretion induced by progesterone in the endometrium during the luteal phase in preparation for nidation. Hum Reprod 2000; 15 Suppl 1: 119-28.   DOI
40 Aboulghar M. Luteal support in reproduction: when, what and how? Curr Opin Obstet Gynecol 2009 Jun; 21: 279-84.   DOI   ScienceOn